Although the effect of azelnidipine for dual blocking of CD47/SIRPα and TIGIT/PVR interactions indeed occurs within one single model, it is hard to distinguish the contribution to the anti-tumor effects of either single blockade. This evidence concerns the gene SIRPA and neoplasm.